QualityDipStocks / Health Care · Pharmaceuticals
AnaptysBio ANAB
Outside our quality screen, so we don’t track its dips. It’s 33% below its 52-week high.
Outside our quality screen, 15% under its Market Value. No fair value estimate for now: the model’s result is too extreme to stand behind.
Worth knowing
- Down 35% from its 52-week high while revenue grew 93%
- Revenue up 93% in a year, top 3% of the 2194 we measure
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- $55.21price −15%
- Off 52-wk high
- −33%
- Risk vs market
- Below marketbeta 0.88
52-week range 52% of the way from its 52-week low to its high
Price $46.91Market Value $55.21
4 bullish · 2 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
Estimate unreliable for ANAB: the model gives 92% below the price; trailing free cash flow is small next to the company's value, so a DCF on it says little. We’d rather show nothing than a made-up number.
What the price implies To be worth today’s price, ANAB’s free cash flow would need to grow about 68% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much ANAB moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves a bit less than the market, and its own price swings are 4.9× the S&P 500’s.
- Beta vs S&P 500
- 0.88
- Volatility
- 63% vs 13% SPY
- Correlation SPY
- 0.18
- Correlation QQQ
- 0.20
How it ranks
Where ANAB stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 2 of 3 measures
- Dividends + buybacks yield0.7% · cash paid out or used to retire shares, vs market capLowest 30%of 2,227
- Revenue growth, last 12 months+93% · vs the 12 months beforeTop 2%of 2,184
- Operating margin91% · of sales kept as operating profitTop 1%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $55.21
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 4 of 5
ProfitabilityOperating margin widened to 96.7% in FY2025 from −958.3% in FY2023 (SEC filings).
ValuationP/E of 9.0× vs a 28.9× median for the 161 Health Care companies we cover.
Cash returnsShare count down 6.4% in a year: $13M of buybacks over 12 months.
ValuationTrades 15.0% below its Market Value of $55.21, the average price paid since the Jun 22 filing.
Top bearish points 2 of 5
ValuationPrice / book of 166.1×, above the 4.8× median for the 291 Health Care companies we cover.
RiskReports earnings Nov 3 (consensus EPS $0.41): results can move the price sharply and reset Market Value.
All fundamentals
P/E 9.0 · Sales +93%
Valuation
- P/E
- 9.0×Health Care median 28.9×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Price / book
- 166.08×
- Market cap
- $1.8Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- n/athe SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Sales growth, 12 months
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Sales growth, 3 yrs
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- Diluted EPS, 12 months
- $5.60
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- $196M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- 90.8%
- Net margin
- n/aneeds total revenue: the SEC revenue tag covers only part of this company's revenue (it is under 1.5x net income)
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- n/anot reported in its SEC filings
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $164M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $13M0.7% of market cap
- Share count, 1 year
- −6.4%diluted shares vs a year ago
- Stock-based comp
- $9M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From AnaptysBio’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +24%
- Free cash flow, 12 months$0.0B
- Gross margin105%
- Operating margin53%
- Return on invested capital38%
- Sales growth (latest quarter vs year-ago quarter)+24%
- Net debt / EBITDA1.6×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $46.91
- 52-wk lowlowest close, 1 year$22.06−53.0%
- PriceMon Nov 2 close$46.91you are here
- Market Valueavg paid since Jun 22$55.21+17.7%
- 52-wk highhighest close, 1 year$69.81+48.8%
Momentum & 52-week range
RSI 43 · 5 days −3.8%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3
- Consensus EPS$0.41
- Year-ago EPS$0.52
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
ANAB is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on AnaptysBio in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.